Head-to-head comparisons of medication uses, side effects, warnings, and more.
Sotyktu (deucravacitinib)
Otezla (apremilast)
Sotyktu (deucravacitinib)
Otezla (apremilast)
Summary of Sotyktu vs. Otezla
Summary for Tyrosine kinase 2 inhibitor
Prescription only
Sotyktu (deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor that's used to treat moderate-to-severe plaque psoriasis in adults. It's a tablet that's taken by mouth once per day. Side effects include a higher risk of infections, such as upper respiratory infections and herpes simplex infections. Sotyktu (deucravacitinib) is a brand-name medication and available by prescription only.
Summary for PDE-4 inhibitor
Prescription only
Otezla (apremilast) is a tablet that's taken by mouth. It's used to treat plaque psoriasis, psoriatic arthritis, and mouth sores from Behçet’s disease. This medication belongs to the drug class called phosphodiesterase-4 (PDE-4) inhibitors. You usually start Otezla (apremilast) at a low dose. Then, the dose is slowly raised over 5 days to lower the risk of side effects like nausea and diarrhea. This medication is available as a brand-name medication. Generic versions of apremilast likely won't be available until at least 2028.